HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report - PubMed
3 hours ago
- #acquired resistance
- #HER2-mutated NSCLC
- #combination therapy
- Trastuzumab deruxtecan (T-DXd) and zongertinib are approved for HER2-mutated advanced NSCLC.
- Resistance to these drugs individually can occur, but combination therapy may overcome acquired resistance, such as HER2 amplification.
- A case report demonstrates a patient responding to combination therapy after progression on each drug alone.